December 2019 - Jay Sparks, host of Finding Unique Value podcast, chats with Dr. Anquetil about how he has leveraged his unique science and business background to create value and solve an unmet need with potential to help millions of people.
If you’re squeamish about needles, you’ll be delighted to know that Portal Instruments is developing technology that will allow needle-free injections of important medications through the skin. It’s especially important for people with chronic conditions that require constant injections.
Portal’s CEO and co-founder, Dr. Patrick Anquetil is DOING THIS. He’s a scientist and engineer who is also able to see the world through the lens of business, allowing him to spot opportunity in a very important industry.
It’s a great example of how business – and even profit – can drive the development of technology with the potential to help millions of people.
Jay Sparks, host of Finding Unique Value podcast, chats with Dr. Anquetil about how he has leveraged his unique science and business background to create value and solve an unmet need with potential to help millions of people.
The podcast discusses Dr. Anquetil’s journey so far, and much more, including…
– How to protect breakthrough inventions with the government’s help
– The hardest part of running a startup and how to overcome it
– Fundraising tips for getting the capital you need
– Why Dr. Anquetil’s education takes a backseat, even in this highly specialized industry
– And more
February 11, 2020 - Gerresheimer recently published an article describing Portal Instrument’s innovative primary drug container which is used in Portal’s needle-free drug delivery platform. Read the full pdf article here.
May 9, 2022 - Gerresheimer AG, a leading provider of drug delivery systems, is expanding its portfolio of highly innovative platform technologies for drug delivery, today announcing an investment into US-based Portal Instruments.
October 2019 - Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.
Please fill out the details below and we will get back to you shortly.